Home - Multimedia
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
MULTIMEDIA
Lundbeck CEO Ulf Wiinberg on patent expiries and future prospects
17 May 2012
Get the Flash Player to see this player.
Podcasts
Lundbeck CEO Ulf Wiinberg on patent expiries and future prospects
17 May 2012
Lundbeck's commercialisation strategy for its Selincro alcohol dependence treatment Selincro (nalmefene) in Europe will necessitate careful identification of suitable patients, and the mechanism of doing that will vary from region to region, Lundbeck CEO Ulf Wiinberg told Scrip in an exclusive interview. Selincro represents an important part of Lundbeck's future prospects after the company navigates its way around the patent expiry of its top-seller Lexapro (escitalopram; Cipralex). Another key part of its future portfolio is its new depression drug Lu AA21004, a product for which Lundbeck expects to make third quarter filings after reporting positive top-line results from three recently completed Phase III studies.
F-star appoints new management team and expands operations in Cambridge, UK
14 May 2012
Dr John Haurum, the new CEO at F-star, explains to Scrip Intelligence editor-in-chief Mike Ward what the arrival of the new management team will mean for the company as it looks to develop its own pipeline and secure a third major alliance in the foreseeable future.
Lundbeck CEO Ulf Wiinberg on patent expiries and future prospects
17 May 2012
Lundbeck's commercialisation strategy for its Selincro alcohol dependence treatment Selincro (nalmefene) in Europe will necessitate careful identification of suitable patients, and the mechanism of doing that will vary from region to region, Lundbeck CEO Ulf Wiinberg told Scrip in an exclusive interview. Selincro represents an important part of Lundbeck's future prospects after the company navigates its way around the patent expiry of its top-seller Lexapro (escitalopram; Cipralex). Another key part of its future portfolio is its new depression drug Lu AA21004, a product for which Lundbeck expects to make third quarter filings after reporting positive top-line results from three recently completed Phase III studies.
F-star appoints new management team and expands operations in Cambridge, UK
14 May 2012
Dr John Haurum, the new CEO at F-star, explains to Scrip Intelligence editor-in-chief Mike Ward what the arrival of the new management team will mean for the company as it looks to develop its own pipeline and secure a third major alliance in the foreseeable future.
Interviews
50 lessons in lifecycle management: Introduction by Christopher Bowe
16 March 2011
US healthcare analyst Christopher Bowe views lifecycle management in the pharmaceutical industry as an artful alchemy of creative foresight, strategy, process management and proactive management, with a goal universal to all companies: getting the most value ethically possible from a compound for as long as possible. www.scripintelligence.com/lifecycle
Executive Briefing: Biomarkers and Beyond. Interview with Dr Peter Charlish
03 March 2011
Scrip analyst Dr Peter Charlish discusses pharma’s drive to enter the companion diagnostics space, challenges facing pharma and diagnostics companies when working together and US and EU regulation for co-developed drugs. Visit scripintelligence.com/biomarkers.
50 lessons in lifecycle management: Introduction by Christopher Bowe
16 March 2011
US healthcare analyst Christopher Bowe views lifecycle management in the pharmaceutical industry as an artful alchemy of creative foresight, strategy, process management and proactive management, with a goal universal to all companies: getting the most value ethically possible from a compound for as long as possible. www.scripintelligence.com/lifecycle
Executive Briefing: Biomarkers and Beyond. Interview with Dr Peter Charlish
03 March 2011
Scrip analyst Dr Peter Charlish discusses pharma’s drive to enter the companion diagnostics space, challenges facing pharma and diagnostics companies when working together and US and EU regulation for co-developed drugs. Visit scripintelligence.com/biomarkers.
Awards
Scrip Awards 2010: Biotech Company of the Year
01 December 2010
Algeta's CEO, Andrew Kay: "This [award] is a reward for all the people of Algeta, and all the hard work they put in."
Scrip Awards 2010: Lifetime Achievement Award
23 November 2010
"Personally, I take it as a tribute to my colleagues with whom I've had the pleasure to be working with for the past 25 years," says Professor John Knowles, who receives the Lifetime Achievement Award for his long academic and commercial career distinguished by a passion for personalised medicine.
Scrip Awards 2010: Biotech Company of the Year
01 December 2010
Algeta's CEO, Andrew Kay: "This [award] is a reward for all the people of Algeta, and all the hard work they put in."
Scrip Awards 2010: Lifetime Achievement Award
23 November 2010
"Personally, I take it as a tribute to my colleagues with whom I've had the pleasure to be working with for the past 25 years," says Professor John Knowles, who receives the Lifetime Achievement Award for his long academic and commercial career distinguished by a passion for personalised medicine.
MULTIMEDIA
